Core Viewpoint - The collaboration between 英矽智能 (InSilico Medicine) and 齐鲁制药集团 (Qilu Pharmaceutical Group) focuses on drug development in the cardiovascular and metabolic disease management sectors, leveraging InSilico's Pharma.AI platform for small molecule inhibitor development [1] Group 1: Collaboration Details - 英矽智能 has signed a strategic cooperation agreement with 齐鲁制药集团 and its subsidiary 上海齐鲁制药研究中心 (Shanghai Qilu Pharmaceutical Research Center) [1] - The partnership will utilize InSilico's proprietary Pharma.AI solutions to develop small molecule inhibitors targeting specific disease pathways [1] Group 2: Financial Aspects - The total value of the agreement exceeds 931 million HKD, which includes milestone payments for development and sales, as well as a share of subsequent net sales [1]
英矽智能与齐鲁制药达成超过9.31亿港元的药物研发合作 加速心血管与代谢类疾病创新疗法开发